Get started
Author

Valeria Solozobova

Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage
2009 · Valeriya Solozobova, Alexandra Rolletschek, et al. · BMC Cell Biology · 104
PDF
p53 in stem cells
2011 · Valeriya Solozobova · World Journal of Biological Chemistry · 85
TRIM25 has a dual function in the p53/Mdm2 circuit
2015 · P Zhang, S Elabd, et al. · Oncogene · 80
Lessons from the Embryonic Neural Stem Cell Niche for Neural Lineage Differentiation of Pluripotent Stem Cells
2012 · Valeriya Solozobova, Nicolas Wyvekens, et al. · Stem Cell Reviews and Reports · 52
PDF
Regulation of p53 in embryonic stem cells
2010 · Valeriya Solozobova, Christine Blattner · Experimental Cell Research · 43
p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53
2015 · H Yan, V Solozobova, et al. · Cell Death and Disease · 17
PDF
Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer
2021 · Nane C. Kuznik, Valeria Solozobova, et al. · ACS Chemical Biology · 16
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway
2022 · Nane C. Kuznik, Valeria Solozobova, et al. · iScience · 13
PDF
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al. · Cancer Research Communications · 12
PDF
TRIM25 targets p300 for degradation
2023 · Seham Elabd, Eleonora Pauletto, et al. · Life Science Alliance · 4
PDF
Oncodevelopmental plasticity of the skeleton in myeloid neoplasms
2026 · Salim Atakhanov, Ian Ghezzi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Figure S1 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Data from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Figure S2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 6 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 7 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Supplementary Data from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Figure S3 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 3 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Figure S4 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 4 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 8 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 5 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
FIGURE 6 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
2023 · Mengwu Pan, Valeria Solozobova, et al.
Works count: 67
Citation count: 427
H-index: 9
I10-index: 9
Year
Topic
Type